Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 3, 2026

Gartner outlines $6.455B revenue target for 2026 as transformation accelerates contract value growth

View original at seekingalpha.com
Gartner outlines $6.455B revenue target for 2026 as transformation accelerates contract value growth Earnings Call Insights: Gartner, Inc…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Clients rarely consider substituting Gartner with AI tools

    80% confidence
  • 2026 Insights revenue expected to be $5.19 billion or more (1% FX-neutral growth)

    80% confidence
  • CV and CV growth rate expected to accelerate over the course of 2026, though the environment still remains pretty chaotic

    80% confidence
  • Contract Value will accelerate in 2026, supported by transformation initiatives

    80% confidence
  • For clients that used AskGartner and then renewed last year, their renewal rates were actually significantly higher

    80% confidence
  • Licensed users who used AskGartner had substantially higher renewal rates than those who did not even with the same levels of engagement

    80% confidence
  • It's going to take a couple of years before we get the full benefit of transformation programs

    80% confidence
  • 2026 consolidated revenue expected to be $6.455 billion or more (2% FX-neutral growth)

    80% confidence
  • Most retention issues are clients reducing seats due to budget constraints, not dissatisfaction

    80% confidence
  • 2026 EBITDA expected to be $1.515 billion or more

    80% confidence
  • 2026 free cash flow expected to be $1.135 billion or more

    80% confidence
  • 23.5% is the new baseline EBITDA margin, and margins should be able to expand going forward

    80% confidence
  • Financial results in the fourth quarter were better than expected and EBITDA margins finished well ahead of initial guidance from February 2025

    80% confidence
  • 2026 Conferences revenue expected to be $695 million or more (7% FX-neutral growth)

    80% confidence
  • DOGE impacts expected to normalize post-Q1 for U.S. federal government clients

    80% confidence
  • The active insights library has grown by approximately 50%

    80% confidence
  • 2026 Consulting revenue expected to be $570 million or more (3% FX-neutral growth)

    80% confidence
  • CV expiration SKU looks pretty consistent with historical patterns, with a little bit more than 25% in each of Q1 and Q4

    80% confidence
  • The single biggest issue we are helping our clients with is AI across every function

    80% confidence
  • 75% time reduction for Insights attributed to new content types, changed process, and automation including AI

    80% confidence
  • The selling environment is going to be no better than it's been in 2025, with variances by industry

    80% confidence
  • External market forces in 2025 led to increased scrutiny, elevated deal approval authority and extended buying cycles

    80% confidence
  • Fourth quarter revenue, EBITDA, margins, EPS and free cash flow were ahead of expectations

    80% confidence
  • CV acceleration expected from lessening federal government headwinds and transformational changes that will build throughout 2026 and into 2027

    80% confidence
  • Gartner repurchased more than $2 billion of stock in 2025

    80% confidence
  • Gartner produced more than 6,000 AI-related documents and had over 200,000 in-depth client conversations on AI in 2025

    80% confidence
  • 2026 adjusted EPS expected to be $12.30 or more

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com